Advanced wound care, made personal

A lightweight device, that fits seamlessly into standard of care A lightweight device, that fits seamlessly into standard of care
Swiss Medical Technology

A lightweight device, that fits seamlessly into standard of care

Get to know our product

The benefits of COMS®-Technology*

Treatment of chronic wounds represents a challenge for both the patient and modern healthcare systems

How it works
Accelerated Wound Closure

Accelerated Wound Closure

To produce a durable closure for hard-to-heal wounds.

Intuitive

Intuitive

Treatment is non-invasive and easy to learn.

Decreased Costs

Decreased Costs

Healing of chronic wounds significantly decreases the financial burden of modern health care.

Platform Technology

Platform Technology

The underlying mechanism of action can be applied to different pathological conditions.


*The COMS® One therapy system is not cleared in the US.

Who are we?

Who are we?

We are a young company founded and based in Zurich, Switzerland since 2016. The Piomic family consists of biologists, designers, engineers, entrepreneurs, young and young-at-heart individuals as well as a broad group of supporters. Staffed with heterogeneous experts from different backgrounds and a common goal: Developing a therapy which is safe and effective in order to set a better future for patients in need.

More about us

Do you want to contribute to our vision?

Do you want to contribute to our vision?

In order to maximize our global impact, we are looking for investors who share our vision and wish to shape the future of wound care with us.

Information for investors

Latest news

European KOLs Initiate NAZARÉ Post-Market Clinical Study

23 Jan 2026

European wound care key opinion leaders initiate NAZARÉ, an investigator-initiated post-market study evaluating COMS® therapy across Europe.

Read more
European KOLs Initiate NAZARÉ Post-Market Clinical Study
FDA Breakthrough Device Designation for COMS® One Therapy System

18 Sep 2025

Piomic Medical Receives FDA Breakthrough Device Designation for its novel COMS® One Therapy System.

Read more
FDA Breakthrough Device Designation for COMS® One Therapy System
MAVERICKS IDE Trial Protocol Published in WOUNDS by Leading U.S. Experts

29 Aug 2025

MAVERICKS study sets new standards in the wound-care industry amid major reimbursement changes.

Read more
MAVERICKS IDE Trial Protocol Published in WOUNDS by Leading U.S. Experts
Piomic Medical Secures Eurostars Financing for COMS® Blue

14 Mar 2025

Piomic Medical secures Eurostars funding for COMS® Blue, advancing antibiotic-independent wound infection treatment with real-time diagnostics and digital health.

Read more
Piomic Medical Secures Eurostars Financing for COMS® Blue
Don't miss our updates!
You must complete your email.
You must accept our Privacy Policy

Our Partners

Do you want to cooperate with us?

We are constantly trying to expand our interdisciplinary know-how and increase the impact of our novel technology on the lives of patients. Therefore we are looking to conncet to the brightest minds in their field of expertise and share our knowledge to create easy-to-use products and innovative wound care solutions.